» Articles » PMID: 30222356

Effects of Protein Corona on Active and Passive Targeting of Cyclic RGD Peptide-Functionalized PEGylation Nanoparticles

Overview
Journal Mol Pharm
Specialty Pharmacology
Date 2018 Sep 18
PMID 30222356
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Protein corona can alter the physiochemical properties of targeting nanoparticles (NPs), as well as their physiological responses and targeting functionality. Herein, we synthesized 20 types of NPs with diverse surface chemistry in order to study the impacts of protein corona on targeting functionality of NPs functionalized with cyclic RGD peptides and their relationships to the polyethylene glycol (PEG) length and grafting density of targeting ligands. After protein adsorption, cyclic RGD on the surface of NP was still able to bind its receptors with increased targeted cellular uptake, even at a relatively low density. However, the cellular uptake was reduced from 26 to 76% when compared with protein nonbound NPs, which was caused by the shielding effect of the outer layer adsorbed proteins. NPs functionalized with short PEG molecules and moderate cyclic RGD density performed a better targeting efficiency. Due to PEG conjugation, the protein corona was demonstrated to be beneficial for passive targeting by decreasing macrophage cellular uptake. These relationships between surface chemistry and targeting functionality will provide guidelines for the design of targeting nanoformulations in nanomedicine.

Citing Articles

Nanomaterial-enabled drug transport systems: a comprehensive exploration of current developments and future avenues in therapeutic delivery.

Basu S, Biswas P, Anto M, Singh N, Mukherjee K 3 Biotech. 2024; 14(12):289.

PMID: 39507057 PMC: 11534931. DOI: 10.1007/s13205-024-04135-y.


MMP13-targeted siRNA-loaded micelles for diagnosis and treatment of posttraumatic osteoarthritis.

Zhou D, Wei Y, Sheng S, Wang M, Lv J, Zhao B Bioact Mater. 2024; 37:378-392.

PMID: 38689658 PMC: 11059470. DOI: 10.1016/j.bioactmat.2024.04.010.


Protein-based nanoparticles for therapeutic nucleic acid delivery.

Eweje F, Walsh M, Ahmad K, Ibrahim V, Alrefai A, Chen J Biomaterials. 2024; 305:122464.

PMID: 38181574 PMC: 10872380. DOI: 10.1016/j.biomaterials.2023.122464.


Effect of the Protein Corona Formation on Antibody Functionalized Liquid Lipid Nanocarriers.

Navarro-Marchal S, Martin-Contreras M, Castro-Santiago D, Del Castillo-Santaella T, Gravan P, Jodar-Reyes A Int J Mol Sci. 2023; 24(23).

PMID: 38069079 PMC: 10706289. DOI: 10.3390/ijms242316759.


Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics.

Kumari M, Acharya A, Krishnamurthy P Beilstein J Nanotechnol. 2023; 14:912-926.

PMID: 37701520 PMC: 10494237. DOI: 10.3762/bjnano.14.75.